Barriers to Warfarin Use for Stroke Prevention in Patients With Atrial Fibrillation in Hong Kong

Authors

  • Vivian W. Y. Lee PharmD, BCPS (AQ Cardiology),

    Corresponding author
    1. School of Pharmacy, Faculty of Medicine, the Chinese University of Hong Kong, Hong Kong
    • School of Pharmacy, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, NT, Hong Kong
    Search for more papers by this author
  • Cheuk Shing Tam BSc,

    1. School of Pharmacy, Faculty of Medicine, the Chinese University of Hong Kong, Hong Kong
    Search for more papers by this author
  • Bryan P. Yan MBBS,

    1. Division of Cardiology, Department of Medicine and Therapeutics, Prince of Wales Hospital, Li Ka Shing Institute of Health and Sciences, Institute of Vascular Medicine, the Chinese University of Hong Kong, Hong Kong
    Search for more papers by this author
  • Cheuk Man Yu MBBS, MD,

    1. Division of Cardiology, Department of Medicine and Therapeutics, Prince of Wales Hospital, Li Ka Shing Institute of Health and Sciences, Institute of Vascular Medicine, the Chinese University of Hong Kong, Hong Kong
    Search for more papers by this author
  • Yat Yin Lam MBBS, MD

    1. Division of Cardiology, Department of Medicine and Therapeutics, Prince of Wales Hospital, Li Ka Shing Institute of Health and Sciences, Institute of Vascular Medicine, the Chinese University of Hong Kong, Hong Kong
    Search for more papers by this author

Abstract

Background:

Oral anticoagulation medications such as warfarin reduce the risk of stroke in atrial fibrillation (AF) but have been underutilized. This study aimed to investigate physicians' perceptions of stroke prevention management and patients' knowledge of AF and warfarin therapy in Hong Kong (HK).

Hypothesis:

Both physician and patient's knowledge on warfarin use were the barriers for stroke prevention in patients with atrial fibrillation in Hong Kong.

Methods:

This prospective survey-based study was conducted between February 2011 and April 2011 to assess physicians' perceptions of stroke prevention management, patients' knowledge of AF, and patients' knowledge of warfarin therapy. The results were scored and compared with those in foreign countries.

Results:

Sixty-two physicians and 114 warfarin users were recruited in the study. The average score of HK physicians in the knowledge of stroke prevention therapy in AF patients was lower than that of Australian (AUS) family physicians (HK 2.48 vs AUS 4.02 out of 7). The mean scores of AF patients in Hong Kong regarding the knowledge of AF were lower than that of United Kingdom (UK) (HK 1.16 vs UK 2.24 out of 4) (P < 0.001) and that of Finland (FIN) (HK 2.77 vs FIN 5.94 out of 8) (P < 0.001), respectively. The mean score of AF patients in Hong Kong regarding the knowledge of warfarin therapy was lower than that of AF patients in the United States (US) (HK 2.39 vs US 3.92).

Conclusions:

The barriers of warfarin use for AF patients in Hong Kong were related to both physicians and patients. Many Hong Kong physicians did not comply with international recommendations of stroke prevention in AF patients, and AF patients had a low knowledge level about the disease and warfarin therapy.

Presented at the International Congress of Cardiology, Hong Kong, Peoples Republic of China, February 24-26, 2012.

This study was supported by the School of Pharmacy, the Chinese University of Hong Kong.

The authors have no other funding, financial relationships, or conflicts of interest to disclose.

Ancillary